BIT Capital GmbH Takes $264,000 Position in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)

Key Points

• BIT Capital GmbH has invested approximately $264,000 in Kiniksa Pharmaceuticals International by acquiring 11,878 shares in the first quarter.
• Kiniksa's stock recently traded up 5.7% to $31.98, with a market cap of $2.33 billion and a year high of $32.15.
• Analysts have raised target prices for Kiniksa Pharmaceuticals, with Wells Fargo increasing its target from $30.00 to $42.00 and giving an "overweight" rating.

BIT Capital GmbH acquired a new position in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 11,878 shares of the company's stock, valued at approximately $264,000.

Other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC increased its holdings in shares of Kiniksa Pharmaceuticals International by 84.8% in the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after acquiring an additional 568 shares during the period. Sound View Wealth Advisors Group LLC grew its stake in shares of Kiniksa Pharmaceuticals International by 4.0% in the 1st quarter. Sound View Wealth Advisors Group LLC now owns 14,657 shares of the company's stock worth $326,000 after purchasing an additional 568 shares during the last quarter. Martingale Asset Management L P grew its stake in shares of Kiniksa Pharmaceuticals International by 1.9% in the 4th quarter. Martingale Asset Management L P now owns 49,360 shares of the company's stock worth $976,000 after purchasing an additional 900 shares during the last quarter. MetLife Investment Management LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 6.3% in the fourth quarter. MetLife Investment Management LLC now owns 23,095 shares of the company's stock worth $457,000 after buying an additional 1,374 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Kiniksa Pharmaceuticals International by 6.7% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,841 shares of the company's stock worth $432,000 after purchasing an additional 1,380 shares during the period. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts recently weighed in on the stock. Wall Street Zen raised shares of Kiniksa Pharmaceuticals International from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 2nd. Jefferies Financial Group increased their price target on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the stock a "buy" rating in a research note on Tuesday, July 29th. Wedbush restated an "outperform" rating and set a $36.00 price target on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Finally, Wells Fargo & Company increased their price target on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 9th. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $41.17.

Insider Buying and Selling at Kiniksa Pharmaceuticals International

In other news, CFO Mark Ragosa sold 18,889 shares of the company's stock in a transaction dated Monday, August 4th. The stock was sold at an average price of $32.89, for a total value of $621,259.21. Following the completion of the sale, the chief financial officer directly owned 27,009 shares of the company's stock, valued at $888,326.01. This represents a 41.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Ross Moat sold 27,594 shares of the firm's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $29.02, for a total transaction of $800,777.88. Following the transaction, the insider directly owned 9,415 shares of the company's stock, valued at $273,223.30. This represents a 74.56% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 332,650 shares of company stock worth $9,705,935 over the last quarter. Corporate insiders own 53.48% of the company's stock.

Kiniksa Pharmaceuticals International Price Performance

KNSA stock traded down $0.19 on Thursday, reaching $32.53. 141,789 shares of the company were exchanged, compared to its average volume of 699,028. Kiniksa Pharmaceuticals International, plc has a 12 month low of $17.82 and a 12 month high of $33.98. The stock's fifty day moving average price is $28.74 and its 200 day moving average price is $24.36. The firm has a market capitalization of $2.37 billion, a PE ratio of 812.58 and a beta of 0.14.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.18 by $0.05. The business had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. As a group, research analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.